Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland
The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.
In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.
“Donors are the linchpin. Not only do I thank you, the World will thank you.”Dr. Web Cavenee
"As a metastatic breast cancer patient undergoing treatment, I intimately know that patients and research are in a marathon. The record speed in the development of the COVID-19 vaccine came from the groundwork of past research. Other diseases demand similar critical attention and research. We have supported NFCR since 1999. We appreciate that their national position promotes a thoughtful continuum where feedback loops from across the country to inform research, coordination, and collaboration. NFCR helps break down the silos that stifle research."ERIKA CORNELISEN
“Cancer is a disease that can be cure…”Albert Szent-Györgyi
Cancer Research is one of the most important things there is. It impacts such a huge number of people and I like that I can help the cause.Jerry Harrington, Donor, Fly to Find a Cure
Donating to the National Foundation for Cancer Research’s Fly to Find a Cure program makes me feel like I’m helping people everywhere, including myself. It’s always wonderful to get the extra mileage to visit the places I want to go.Betty Locke, Donor, Fly to Find a Cure